Editas Medicine sought regulatory feedback from the FDA on clinical trials and listed its shares on an exchange on May 27, 2026.
4 reports, 2 independent
Updated Aug 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Editas Medicine sought regulatory feedback from the FDA on clinical trials and listed its shares on an exchange on May 27, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Editas Medicine
discovery-phase pharmaceutical company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
Related events
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Mylan is seeking regulatory approval from the FDA for new products and has listed its stock on the Nasdaq exchange.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.